United States Patent 10,729,823: Scope, Claim Architecture, and US Patent Landscape
US Patent 10,729,823 is directed to an intravesical, elastically deformable drug delivery device that uses an osmotic agent to drive in vivo release of a drug from a water-permeable, annular or tubular housing. The core claim pattern is a two-position, fluidly communicating dual “unit” system (drug unit and osmotic-agent unit) arranged relative to a drug-release orifice and configured for straight-to-retention shape transformation after urethral insertion into the bladder.
The claims cover both (i) a single-drug unit versus osmotic-agent unit architecture with positional separation, and (ii) a multiple tablet version with defined axial regions, including specific embodiments for gemcitabine + urea and zero-order kinetics over 2 to 14 days.
What does claim 1 actually cover? (Independent claim scope)
Claim 1: Device elements and functional requirements
Claim 1 recites an intravesical drug delivery device with the following required features:
-
Housing / reservoir
- A housing defining a reservoir
- The housing is an elongated, annular tube
- The reservoir is an annulus of the annular tube
-
Two contained units in distinct axial positions
- First unit contained in the reservoir at a first position
- First unit comprises a drug
- Second unit contained in the reservoir at a second position distinct from the first
- First unit and second unit positions are in fluid communication
- The second unit comprises an osmotic agent
- Osmotic agent facilitates in vivo release of the drug from the housing
-
Orifice-based release
- A drug release orifice is provided in:
- (i) an end plug at an end of the tube, or
- (ii) a sidewall of the tube
- The first unit is located closer than the second unit to the drug release orifice
-
Elastically deformable insertion and retention
- The device is elastically deformable between:
- a relatively straightened shape suited for insertion through the urethra
- a retention shape suited to retain the device within the bladder
This combination creates a device that is not merely a bladder insert, but a specific mechanical and fluidic architecture:
- mechanical: straight-to-retention deformability for placement and retention
- fluidic: osmotic in vivo release with urine-mediated solubilization
- positional: the drug is axially closer to the orifice than the osmotic agent
- release geometry: orifice at end plug or sidewall
Claim 1: Minimum novelty hooks likely used for patentability
Based on the claim text, the likely distinguishing points relative to more general intravesical osmotic systems are:
- annular tube / annulus reservoir form factor (elongated, annular)
- dual-unit axial staging with the drug unit closer to the orifice
- orifice placement flexibility (end plug or sidewall)
- elastically deformable straight-to-retention device form factor
How do dependent claims narrow or extend the technology?
Water permeability / barrier language
- Claim 2: Housing includes a water permeable wall portion defining at least part of reservoir.
- Claim 3: Water permeable wall portion is substantially impermeable to the drug in aqueous solution.
- Claim 6-7: Housing is an elongated annular tube with a water permeable portion and a water impermeable portion, with the impermeable portion having a water impermeable coating.
Landscape implication: This is a claim strategy that ties release behavior to material permeability and drug partitioning across the tube wall, not just to osmotic pressure.
Drug solubility class and drug selection
- Claim 4: Drug is a low solubility drug.
- Claim 11: Drug comprises one of a listed set including:
- lidocaine
- gemcitabine
- docetaxel
- carboplatin
- cisplatin
- oxaliplatin
- trospium
- tolterodine
- mitomycin C
- Claim 12: Gemcitabine with osmotic agent urea
- Claim 13: Gemcitabine HCl ≥75 wt% in first unit; urea ≥85 wt% in second unit
Landscape implication: The patent is broad across multiple intravesical drugs but contains a strong, tightly defined gemcitabine + urea sub-scope.
Tablet form factors
- Claim 5: Units can be solid tablets (single-unit or both units).
- Claim 14-15: Axial packing geometry for annular tube:
- inner diameter 2 to 5 mm
- first plurality of tablets fills 1 to 3 cm
- second plurality fills 10 to 15 cm
- volume ratio (first plurality / second plurality) 0.05 to 0.5
Landscape implication: Adds a manufacturable packing profile and axial separation, which can be a key differentiator in validity and design-around.
Mechanical retention architecture
- Claim 16: Device spontaneously assumes a shape with an interconnected and overlapping pair of coils in absence of compressive load.
Landscape implication: The “coils” limitation narrows to a particular retention mechanism, but also provides a mechanical differentiator for devices aiming for bladder retention.
Internal flow modulator
- Claim 17: A flow modulator channel is disposed in reservoir between the first and second units.
Landscape implication: Introduces an additional internal transport-control element that can materially affect release profile and may separate the device from simpler layered-osmotic arrangements.
Specific release mechanism framing
- Claim 18-19: Water permeable housing + drug tablet at first position + osmotic-agent tablet at second position + release by osmotic pressure; osmotic agent urea.
Method claims
- Claim 20: Method of administering includes inserting device and releasing drug.
- Claim 21-22: Inserting into bladder; urine enters reservoir and solubilizes drug and osmotic agent.
- Claim 23: With gemcitabine + urea: release is zero order over 2 to 14 days.
What about claims 24-31? (Second independent claim track and specific embodiments)
Claims 24 and 25-31 create a parallel embodiment strategy:
Claim 24: general multi-unit version
- Similar elastically deformable straight-to-retention device
- Requires a plurality of:
- solid first units (drug)
- solid second units (osmotic agent)
- No explicit “annular tube + annulus” phrasing in the excerpted text for claim 24; it focuses on general housing and dual unit multiplicity.
Claim 25: water-permeable elastomeric tube + orifice + tablet arrays
- Housing is a water permeable elastomeric tube
- has lumen defining reservoir
- has drug release orifice in communication with reservoir
- Includes:
- plurality of first tablets with drug at one or more first positions
- plurality of second tablets with osmotic agent at one or more second positions different from first positions, fluidly communicating
- Device solubilization logic:
- after intravesical insertion, urine diffuses in and solubilizes tablets
- solubilized drug releases through orifice by osmotic pressure
Claim 26: positional relation to orifice
- First tablets are located closer than second tablets to the drug release orifice.
Claim 28: axial regional arrangement + orifice adjacency
- Second tablets positioned in opposed end regions
- First tablets positioned in a middle region
- Drug release orifice located in sidewall adjacent to first tablets
Claim 29-31: specific gemcitabine + urea + axial placement
- Housing: water permeable silicone tube
- Cylindrical reservoir + sidewall drug release orifice
- Drug tablets:
- at least 75 wt% gemcitabine
- Osmotic agent tablets:
- Osmotic agent tablets positioned within opposed end regions
- Drug tablets positioned within middle region
- Claim 30: Drug tablets are centered about orifice
- Claim 31: Release logic by urine solubilization and osmotic pressure through orifice
Landscape implication: Claims 29-31 are the tightest “commercially legible” sub-claims: material (silicone tube), composition thresholds, and axial placement.
Claim coverage map: what is broad vs what is specific
| Feature |
Included in broad core? |
Where it becomes explicit / narrowed |
| Intravesical insertion + bladder retention via elastically deformable device |
Yes (Claim 1) |
Claim 16 (coil mechanics) |
| Water-permeable housing wall |
Claim 1 is not explicit; Claim 2 makes it explicit |
Claims 2-3, 6-7, 25, 29 |
| Water impermeable portion/coating |
Not in Claim 1 |
Claims 6-7 |
| Annular tube / annulus reservoir |
Yes (Claim 1) |
Claim 14 references annular geometry |
| Tabletized units |
Yes via Claim 5 (optional form) |
Claim 25-26, 28-29 |
| Dual units in distinct positions with fluid communication |
Yes |
Core of Claims 1 and 25 |
| Osmotic agent in second unit |
Yes |
Claim 12-13, 18-19, 27, 29 |
| Gemcitabine + urea specifically |
Not required in Claim 1 |
Claims 12-13, 18-19, 23, 27, 29-31 |
| Orifice placement (end plug or sidewall) |
Yes (Claim 1) |
Claim 25-31 emphasize sidewall orifice |
| Drug unit closer to orifice |
Yes |
Claim 26 and Claim 14 (ratio/lengths add specificity) |
| Defined axial length ranges |
Not in Claim 1 |
Claim 14 (1-3 cm drug, 10-15 cm osmotic) |
| Defined zero-order kinetics duration |
Not in device structure |
Claim 23 (2-14 days) |
| Specific device materials list |
Not in Claim 1 |
Claim 10 (silicone, TPU, EVA) and Claim 29 (silicone) |
US patent landscape: likely impact areas (device class + drug class + mechanism)
1) Mechanism overlap: intravesical osmotic controlled release
The claims sit in a category where competitors and earlier filers commonly claim:
- osmotic pressure-driven release in vivo
- urine-mediated solubilization
- controlled release kinetics (often zero-order or near-zero-order)
- multi-compartment reservoir designs
In US prosecution and FTO terms, 10,729,823’s key differentiator is not osmotic release alone; it is the combination of:
- elastically deformable straight-to-retention form
- tube/annular housing with water permeability and possible drug-impermeable coating
- axial positioning of drug and osmotic agent relative to a drug-release orifice
2) Mechanical retention differentiation: coil-based shape assumption
Claim 16 introduces a mechanical retention feature (interconnected and overlapping pair of coils) tied to spontaneous shape assumption. Devices that retain by:
- balloon,
- rigid expansion elements,
- inflatable structures,
- or purely hydrodynamic retention
could fall outside this mechanical element, depending on claim interpretation.
3) Orifice and axial staging as design-around vectors
Two major risk levers for freedom to operate:
- orifice location (end plug vs sidewall adjacency)
- relative axial positioning (drug closer than osmotic agent; middle-region drug with end-region osmotic agent)
If competitors shift the relative distance such that the drug unit is not closer than the osmotic unit to the orifice, they may avoid key limitations in Claims 1 and 26. If competitors provide the orifice in a manner inconsistent with the claim language (for example, fully interior-only release with no sidewall/end-plug defined orifice), risk depends on how broadly “drug release orifice” is interpreted.
4) Gemcitabine + urea commercial focus
Claims 12-13, 18-19, 23, 27, and 29-31 tie the device explicitly to gemcitabine and urea with composition thresholds:
- gemcitabine HCl ≥75 wt% (Claim 13)
- urea ≥85 wt% (Claim 13)
- gemcitabine ≥75 wt% (Claim 29)
- urea ≥85 wt% (Claim 29)
For landscape mapping, this means the most enforceable lane is the specific pairing and packing logic, not just osmotic release.
Practical infringement-risk synthesis (element-by-element)
High-risk for competitors using the same architectural template
Risk is elevated for intravesical devices that include all of:
- elastically deformable straight insertion and retention in bladder
- water-permeable tube/annular housing
- drug tablets in an axial region closer to a drug-release orifice
- osmotic agent tablets in a separate axial region fluidly communicating with drug tablets
- orifice release via osmotic pressure
- urine solubilization of both drug and osmotic components
Moderate-risk for partial overlaps
Competitors likely face moderate risk if they match:
- osmotic dual-compartment release but use different mechanical retention (non-coil, different deformation element), or
- match the mechanical retention but change tablet placement relative to orifice, or
- match the gel/film release but not the explicit dual-unit positioned arrangement.
Lower-risk if key claim anchors are removed
Lower risk if a product:
- does not provide an orifice as claimed (or release is through different structural termination), or
- does not split drug and osmotic agent into distinct axial positions in fluid communication, or
- uses a different release driver (not osmotic-agent-facilitated release).
Key claim benchmarks to use in US patent landscape screening
These are the recurring “search and map” anchors that control how you compare competing filings to 10,729,823:
- Intravesical elastically deformable delivery device
- Water-permeable tube or annular tube reservoir
- Two distinct axial positions of dual units
- first unit drug
- second unit osmotic agent
- fluid communication between positions
- Orifice release
- end plug or sidewall
- drug unit positioned closer to orifice
- Gemcitabine + urea option
- Tablet stacking axial lengths
- 1-3 cm drug region and 10-15 cm osmotic region (Claim 14)
- Zero-order release duration
- Coil-based retention shape
- interconnected overlapping pair of coils (Claim 16)
Key Takeaways
- US 10,729,823 claims a specific intravesical osmotic controlled-release device defined by (i) straight-to-retention elastically deformable mechanics, (ii) a water-permeable tubular/annular reservoir, (iii) dual drug vs osmotic-agent units in distinct but fluidly communicating axial positions, and (iv) a drug-release orifice with the drug unit located closer than the osmotic unit.
- The most enforceable commercial lane is the gemcitabine + urea implementations, reinforced by composition thresholds and, in at least one claim, zero-order release over 2 to 14 days.
- For freedom-to-operate screening, the highest leverage differentiators are orifice location, axial staging relative to the orifice, fluid communication between units, and the deformation/retention mechanism.
FAQs
1) What is the central claim theme of US 10,729,823?
An intravesical delivery device that uses osmotic agent-driven release from a water-permeable tube/annular reservoir, with drug and osmotic-agent units positioned separately and arranged relative to a drug-release orifice, combined with elastically deformable straight-to-retention insertion/retention.
2) Does the patent require gemcitabine and urea?
No. Gemcitabine and urea are explicit in dependent claims, with tighter sub-scope protections. The independent architecture is broader across listed drugs but the strongest specific embodiments are gemcitabine + urea.
3) What release-control features are repeatedly required across the claim set?
Urine-mediated solubilization into a reservoir, osmotic-agent facilitation of drug release, and release through a defined drug-release orifice, with the drug unit positioned closer to the orifice than the osmotic-agent unit.
4) Where is the drug release orifice permitted?
Claim 1 allows an orifice in either an end plug or a sidewall. The later embodiments emphasize a sidewall orifice in water-permeable tube/silicone tube configurations.
5) What mechanical feature could create design-around opportunities?
Claim 16’s coil-based spontaneous retention shape is a narrowing limitation; devices that achieve bladder retention without the claimed coil mechanics may reduce alignment with that dependent claim path, depending on how the independent claim is construed.
References
[1] United States Patent No. 10,729,823.
